87 studies found for:    Open Studies | "Epstein-Barr Virus Infections"
Show Display Options
Rank Status Study
21 Recruiting Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Conditions: Non-Hodgkin Lymphoma;   Burkitt Lymphoma;   Diffuse Large B-Cell Lymphoma;   Primary Mediastinal B-cell Lymphoma;   CD20+ Lymphoblastic Lymphoma;   Follicular Lymphoma, Grade III
Interventions: Drug: Obinutuzumab;   Drug: Liposomal ARA-C;   Drug: Ifosfamide;   Drug: Carboplatin;   Drug: Etoposide
22 Recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large B-cell Lymphoma;   AIDS-Related Plasmablastic Lymphoma;   AIDS-Related Primary Effusion Lymphoma;   HIV Infection
Interventions: Drug: Prednisone;   Biological: Rituximab;   Drug: Etoposide;   Drug: Doxorubicin Hydrochloride;   Drug: Vincristine Sulfate;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Biological: Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
23 Not yet recruiting Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Drug: lenalidomide;   Drug: romidepsin;   Other: laboratory biomarker analysis
24 Recruiting Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients
Conditions: B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia;   Refractory B-cell Acute Lymphoblastic Leukemia
Intervention: Biological: CTL019 T-cells
25 Not yet recruiting Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia
Conditions: Relapsed or Refractory Acute Myeloid Leukemia;   Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Intervention: Drug: VS-4718
26 Recruiting Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)
Condition: Leukemia
Interventions: Drug: Ofatumumab;   Drug: Etoposide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Prednisone;   Drug: Rituximab;   Drug: Pegfilgrastim;   Drug: G-CSF;   Behavioral: Phone Calls
27 Recruiting CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
28 Recruiting Study of Efficacy and Safety of CTL019 in Adult ALL Patients
Conditions: B-cell Acute Lymphoblastic Leukemia;   Relapsed B-cell Acute Lymphoblastic Leukemia;   Refractory B-cell Acute Lymphoblastic Leukemia
Intervention: Drug: CTL019
29 Recruiting Cellular Immunotherapy Following Cyclophosphamide in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia
Conditions: Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Waldenström Macroglobulinemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
Interventions: Drug: cyclophosphamide;   Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate
30 Recruiting Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Conditions: Acute Leukemias;   Burkitt's Lymphoma;   Chronic Myelogenous Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Haploidentical stem cell transplant
31 Recruiting Yoga Fatigue Study
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia in Relapse;   Burkitt's Lymphoma Stage III;   Burkitt's Lymphoma Stage IV;   Type 3 Diffuse Large B-Cell Lymphoma
Interventions: Behavioral: Individualized Yoga Intervention Group;   Other: iPad Activity Control Group
32 Recruiting Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis
33 Recruiting Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
Conditions: Adult B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
34 Recruiting Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors
Conditions: Solid Tumor;   Ovarian Cancer;   Non-small Cell Lung Cancer;   Chronic Lymphocytic Leukemia;   Burkitt's Lymphoma
Intervention:
35 Recruiting Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
Condition: B-cell Acute Lymphoblastic Leukemia
Intervention: Other: anti-CD19 redirected NK cells
36 Not yet recruiting Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Conditions: Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
37 Recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   HIV Infection
Interventions: Drug: busulfan;   Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Other: pharmacological study;   Other: laboratory biomarker analysis
38 Recruiting Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma;   Diffuse Large Cell Lymphoma;   'Grey Zone' Lymphoma;   Lymphoblastic Lymphoma;   Anaplastic Large Cell Lymphoma;   Hodgkin Lymphoma
Intervention: Drug: CPX-351
39 Recruiting Safety and Tolerability of HSC835 in Patients Undergoing Single Umbilical Cord Blood Transplant
Conditions: Single Umbilical Cord Blood Transplantation;   Non-myeloablative Conditioning;   Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Chronic Lymphocytic Leukemia;   Marginal Zone Lymphoma;   Follicular Lymphomas;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Mantle-cell Lymphoma;   Lymphoplasmacytic Lymphoma;   Prolymphocytic Leukemia
Intervention: Drug: HSC835
40 Recruiting S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Conditions: Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years